Market Cap 28.22M
Revenue (ttm) 6.44M
Net Income (ttm) 183.45M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 2,848.60%
Debt to Equity Ratio 0.00
Volume 4,000
Avg Vol 17,886
Day's Range N/A - N/A
Shares Out 4.05M
Stochastic %K 27%
Beta 1.01
Analysts Sell
Price Target $36.50

Company Profile

Kyntra Bio, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing FG-3246, a potential antibody-drug conjugate targeting CD46, for the treatment of metastatic castration-resistant prostate cancer and other cancers. It is also developing Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment...

Industry: Biotechnology
Sector: Healthcare
Phone: 415 978 1200
Fax: 415 978 1902
Address:
350 Bay Street, Suite 100 #6009, San Francisco, United States
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 23 at 8:53 AM
$KYNB New review in Frontiers in Bioengineering and Biotechnology explores the molecular mechanisms and clinical potential of HIF-PH inhibitors, including Roxadustat, in anemia treatment. Good supporting scientific background. https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2026.1708887/pdf
1 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 23 at 8:52 AM
$KYNB New systematic review and meta-analysis published in Journal of Clinical Medicine confirms that Roxadustat significantly improves hemoglobin levels in CKD patients compared to placebo. Good supporting data for the drug. https://www.mdpi.com/2571-6980/7/3/18
0 · Reply
MaxMiamiFl
MaxMiamiFl Jun. 22 at 3:18 PM
$KYNB just for the hell of it 😂
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 21 at 10:22 AM
$KYNB New publication in Frontiers in Immunology explores Roxadustat's potential immunomodulatory effects in autoimmune and inflammatory conditions. Interesting expansion of possible applications. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1780245/full
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 21 at 10:21 AM
$KYNB German review article discusses optimization of anemia treatment in CKD, comparing ESA and HIF-PHI (including Roxadustat) for both dialysis and non-dialysis patients. Useful clinical overview. https://www.researchgate.net/publication/407283110_Management_der_Anamie_bei_chronischer_Nierenerkrankung_Optimierung_des_Einsatzes_von_ESA_und_HIF-PHI_bei_Dialyse-_und_Nicht-Dialysepatienten
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 21 at 10:20 AM
$KYNB New study in International Journal of Molecular Sciences examines Roxadustat's effects on oxidative stress and kidney protection in disease models. Supportive preclinical data. https://www.mdpi.com/1422-0067/27/12/5501
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 19 at 3:18 PM
$KYNB New publication in Lupus Science & Medicine examines Roxadustat use in patients with lupus nephritis. Expanding possible applications for the drug. https://lupus.bmj.com/content/13/1/e002146
1 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 19 at 3:18 PM
$KYNB Preclinical study shows Roxadustat may help reduce oxidative stress and inflammation in kidney disease models. Interesting additional potential beyond anemia correction. https://www.mdpi.com/1422-0067/27/12/5506
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 19 at 3:18 PM
$KYNB Review article discusses the mechanisms of HIF-PH inhibitors like Roxadustat in anemia and inflammation. Good scientific background for the drug class. https://www.sciencedirect.com/science/article/pii/S2590006426003443
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 19 at 3:18 PM
$KYNB New study explores the potential of Roxadustat in lupus nephritis — a promising signal for treating multifactorial anemia in autoimmune kidney disease. https://www.researchgate.net/publication/407153617_Roxadustat_in_lupus_nephritis_a_novel_therapeutic_signal_for_multifactorial_anaemia
0 · Reply
Latest News on KYNB
Kyntra Bio Transcript: AGM 2026

Jun 12, 2026, 11:00 AM EDT - 12 days ago

Kyntra Bio Transcript: AGM 2026


Kyntra Bio to present additional MATTERHORN trial data at EHA

2026-06-11T20:20:00.000Z - 13 days ago

Kyntra Bio to present additional MATTERHORN trial data at EHA


Kyntra Bio initiated with a Buy at Rodman & Renshaw

2026-06-09T11:16:47.000Z - 16 days ago

Kyntra Bio initiated with a Buy at Rodman & Renshaw


Kyntra Bio Earnings Call Transcript: Q1 2026

May 11, 2026, 5:00 PM EDT - 6 weeks ago

Kyntra Bio Earnings Call Transcript: Q1 2026


Kyntra Bio Earnings release: Q1 2026

May 11, 2026, 5:00 PM EDT - 6 weeks ago

Kyntra Bio Earnings release: Q1 2026


Kyntra Bio Slides: Q1 2026

May 11, 2026, 5:00 PM EDT - 6 weeks ago

Kyntra Bio Slides: Q1 2026


Kyntra Bio Quarterly report: Q1 2026

May 11, 2026, 5:00 PM EDT - 6 weeks ago

Kyntra Bio Quarterly report: Q1 2026


Kyntra Bio to Report First Quarter 2026 Financial Results

May 4, 2026, 4:05 PM EDT - 7 weeks ago

Kyntra Bio to Report First Quarter 2026 Financial Results


Kyntra Bio Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Kyntra Bio Proxy statement: Proxy filing


Kyntra Bio Proxy statement: Proxy filing

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Kyntra Bio Proxy statement: Proxy filing


Kyntra Bio Earnings Call Transcript: Q4 2025

Mar 16, 2026, 5:00 PM EDT - 3 months ago

Kyntra Bio Earnings Call Transcript: Q4 2025


Kyntra Bio Annual report: Q4 2025

Mar 16, 2026, 5:00 PM EDT - 3 months ago

Kyntra Bio Annual report: Q4 2025


Kyntra Bio Earnings release: Q4 2025

Mar 16, 2026, 5:00 PM EDT - 3 months ago

Kyntra Bio Earnings release: Q4 2025


Kyntra Bio Slides: Q4 2025

Mar 16, 2026, 5:00 PM EDT - 3 months ago

Kyntra Bio Slides: Q4 2025


Kyntra Bio Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 2:20 PM EDT - 3 months ago

Kyntra Bio Transcript: Leerink Global Healthcare Conference 2026


Kyntra Bio Slides: Corporate presentation

Mar 11, 2026, 7:00 AM EDT - 3 months ago

Kyntra Bio Slides: Corporate presentation


Kyntra Bio to Participate in Upcoming Investor Conferences

Feb 17, 2026, 4:05 PM EST - 4 months ago

Kyntra Bio to Participate in Upcoming Investor Conferences


Kyntra Bio Earnings Call Transcript: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

Kyntra Bio Earnings Call Transcript: Q3 2025


Kyntra Bio Quarterly report: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

Kyntra Bio Quarterly report: Q3 2025


Kyntra Bio Earnings release: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

Kyntra Bio Earnings release: Q3 2025


Kyntra Bio Slides: Q3 2025

Nov 10, 2025, 5:00 PM EST - 8 months ago

Kyntra Bio Slides: Q3 2025


FibroGen to Report Third Quarter 2025 Financial Results

Nov 3, 2025, 4:02 PM EST - 8 months ago

FibroGen to Report Third Quarter 2025 Financial Results


Kyntra Bio Earnings Call Transcript: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 11 months ago

Kyntra Bio Earnings Call Transcript: Q2 2025


Kyntra Bio Quarterly report: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 11 months ago

Kyntra Bio Quarterly report: Q2 2025


Kyntra Bio Earnings release: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 11 months ago

Kyntra Bio Earnings release: Q2 2025


Kyntra Bio Slides: Q2 2025

Aug 11, 2025, 5:00 PM EDT - 11 months ago

Kyntra Bio Slides: Q2 2025


FibroGen to Report Second Quarter 2025 Financial Results

Aug 4, 2025, 4:02 PM EDT - 11 months ago

FibroGen to Report Second Quarter 2025 Financial Results


FibroGen Announces 1-for-25 Reverse Stock Split

Jun 12, 2025, 4:02 PM EDT - 1 year ago

FibroGen Announces 1-for-25 Reverse Stock Split


Kyntra Bio Earnings Call Transcript: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings Call Transcript: Q1 2025


Kyntra Bio Quarterly report: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Quarterly report: Q1 2025


Kyntra Bio Earnings release: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings release: Q1 2025


Kyntra Bio Slides: Q1 2025

May 12, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Slides: Q1 2025


FibroGen to Report First Quarter 2025 Financial Results

May 5, 2025, 4:05 PM EDT - 1 year ago

FibroGen to Report First Quarter 2025 Financial Results


Kyntra Bio Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Kyntra Bio Proxy statement: Proxy Filing


Kyntra Bio Proxy statement: Proxy Filing

Apr 25, 2025, 8:00 AM EDT - 1 year ago

Kyntra Bio Proxy statement: Proxy Filing


Kyntra Bio Proxy statement: Proxy Filing

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Kyntra Bio Proxy statement: Proxy Filing


Kyntra Bio Earnings Call Transcript: Q4 2024

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings Call Transcript: Q4 2024


Kyntra Bio Annual report: Q4 2024

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Annual report: Q4 2024


Kyntra Bio Earnings release: Q4 2024

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Earnings release: Q4 2024


Kyntra Bio Slides: Q4 2024

Mar 17, 2025, 5:00 PM EDT - 1 year ago

Kyntra Bio Slides: Q4 2024


Kyntra Bio Transcript: Status Update

Feb 20, 2025, 8:30 AM EST - 1 year ago

Kyntra Bio Transcript: Status Update


Kyntra Bio Press release: Status Update

Feb 20, 2025, 8:30 AM EST - 1 year ago

Kyntra Bio Press release: Status Update


Kyntra Bio Slides: Status Update

Feb 20, 2025, 8:30 AM EST - 1 year ago

Kyntra Bio Slides: Status Update


FibroGen Appoints David DeLucia as Chief Financial Officer

Dec 16, 2024, 8:05 AM EST - 1 year ago

FibroGen Appoints David DeLucia as Chief Financial Officer


Kyntra Bio Earnings Call Transcript: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Earnings Call Transcript: Q3 2024


Kyntra Bio Quarterly report: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Quarterly report: Q3 2024


Kyntra Bio Earnings release: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Earnings release: Q3 2024


Kyntra Bio Slides: Q3 2024

Nov 12, 2024, 5:00 PM EST - 1 year ago

Kyntra Bio Slides: Q3 2024


FibroGen Reports Third Quarter 2024 Financial Results

Nov 12, 2024, 4:05 PM EST - 1 year ago

FibroGen Reports Third Quarter 2024 Financial Results


FibroGen to Report Third Quarter 2024 Financial Results

Nov 4, 2024, 4:05 PM EST - 1 year ago

FibroGen to Report Third Quarter 2024 Financial Results


Kyntra Bio Earnings Call Transcript: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Earnings Call Transcript: Q2 2024


Kyntra Bio Quarterly report: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Quarterly report: Q2 2024


Kyntra Bio Earnings release: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Earnings release: Q2 2024


Kyntra Bio Slides: Q2 2024

Aug 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Slides: Q2 2024


FibroGen to Report Second Quarter 2024 Financial Results

Jul 30, 2024, 4:07 PM EDT - 2 years ago

FibroGen to Report Second Quarter 2024 Financial Results


Kyntra Bio Registration statement: Registration Filing

Jun 28, 2024, 8:00 AM EDT - 2 years ago

Kyntra Bio Registration statement: Registration Filing


FibroGen to Participate in Upcoming Investor Conferences

May 7, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Participate in Upcoming Investor Conferences


Kyntra Bio Earnings Call Transcript: Q1 2024

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Earnings Call Transcript: Q1 2024


Kyntra Bio Quarterly report: Q1 2024

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Quarterly report: Q1 2024


Kyntra Bio Earnings release: Q1 2024

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Earnings release: Q1 2024


Kyntra Bio Slides: Q1 2024

May 6, 2024, 5:00 PM EDT - 2 years ago

Kyntra Bio Slides: Q1 2024


FibroGen Reports First Quarter 2024 Financial Results

May 6, 2024, 4:02 PM EDT - 2 years ago

FibroGen Reports First Quarter 2024 Financial Results


FibroGen to Report First Quarter 2024 Financial Results

Apr 29, 2024, 7:00 AM EDT - 2 years ago

FibroGen to Report First Quarter 2024 Financial Results


Kyntra Bio Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Kyntra Bio Proxy statement: Proxy Filing


Kyntra Bio Proxy statement: Proxy Filing

Apr 24, 2024, 8:00 AM EDT - 2 years ago

Kyntra Bio Proxy statement: Proxy Filing


FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer

Mar 11, 2024, 7:00 AM EDT - 2 years ago

FibroGen Appoints Deyaa Adib, M.D. as Chief Medical Officer


Kyntra Bio Earnings Call Transcript: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings Call Transcript: Q4 2023


Kyntra Bio Annual report: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Annual report: Q4 2023


Kyntra Bio Earnings release: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings release: Q4 2023


Kyntra Bio Slides: Q4 2023

Feb 26, 2024, 5:00 PM EST - 2 years ago

Kyntra Bio Slides: Q4 2023


FibroGen regains rights to anemia drug from AstraZeneca

Feb 26, 2024, 4:18 PM EST - 2 years ago

FibroGen regains rights to anemia drug from AstraZeneca

AZN


Kyntra Bio Transcript: Study Update

Feb 13, 2024, 10:30 AM EST - 2 years ago

Kyntra Bio Transcript: Study Update


Kyntra Bio Slides: Corporate Presentation

Jan 10, 2024, 3:00 PM EST - 2 years ago

Kyntra Bio Slides: Corporate Presentation


Kyntra Bio Earnings Call Transcript: Q3 2023

Nov 6, 2023, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings Call Transcript: Q3 2023


Kyntra Bio Quarterly report: Q3 2023

Nov 6, 2023, 5:00 PM EST - 2 years ago

Kyntra Bio Quarterly report: Q3 2023


Kyntra Bio Earnings release: Q3 2023

Nov 6, 2023, 5:00 PM EST - 2 years ago

Kyntra Bio Earnings release: Q3 2023


Kyntra Bio Slides: Q3 2023

Nov 6, 2023, 5:00 PM EST - 2 years ago

Kyntra Bio Slides: Q3 2023


FibroGen Reports Third Quarter 2023 Financial Results

Nov 6, 2023, 4:01 PM EST - 2 years ago

FibroGen Reports Third Quarter 2023 Financial Results


FibroGen to Report Third Quarter 2023 Financial Results

Oct 23, 2023, 7:00 AM EDT - 2 years ago

FibroGen to Report Third Quarter 2023 Financial Results


ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 23 at 8:53 AM
$KYNB New review in Frontiers in Bioengineering and Biotechnology explores the molecular mechanisms and clinical potential of HIF-PH inhibitors, including Roxadustat, in anemia treatment. Good supporting scientific background. https://www.frontiersin.org/journals/bioengineering-and-biotechnology/articles/10.3389/fbioe.2026.1708887/pdf
1 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 23 at 8:52 AM
$KYNB New systematic review and meta-analysis published in Journal of Clinical Medicine confirms that Roxadustat significantly improves hemoglobin levels in CKD patients compared to placebo. Good supporting data for the drug. https://www.mdpi.com/2571-6980/7/3/18
0 · Reply
MaxMiamiFl
MaxMiamiFl Jun. 22 at 3:18 PM
$KYNB just for the hell of it 😂
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 21 at 10:22 AM
$KYNB New publication in Frontiers in Immunology explores Roxadustat's potential immunomodulatory effects in autoimmune and inflammatory conditions. Interesting expansion of possible applications. https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1780245/full
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 21 at 10:21 AM
$KYNB German review article discusses optimization of anemia treatment in CKD, comparing ESA and HIF-PHI (including Roxadustat) for both dialysis and non-dialysis patients. Useful clinical overview. https://www.researchgate.net/publication/407283110_Management_der_Anamie_bei_chronischer_Nierenerkrankung_Optimierung_des_Einsatzes_von_ESA_und_HIF-PHI_bei_Dialyse-_und_Nicht-Dialysepatienten
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 21 at 10:20 AM
$KYNB New study in International Journal of Molecular Sciences examines Roxadustat's effects on oxidative stress and kidney protection in disease models. Supportive preclinical data. https://www.mdpi.com/1422-0067/27/12/5501
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 19 at 3:18 PM
$KYNB New publication in Lupus Science & Medicine examines Roxadustat use in patients with lupus nephritis. Expanding possible applications for the drug. https://lupus.bmj.com/content/13/1/e002146
1 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 19 at 3:18 PM
$KYNB Preclinical study shows Roxadustat may help reduce oxidative stress and inflammation in kidney disease models. Interesting additional potential beyond anemia correction. https://www.mdpi.com/1422-0067/27/12/5506
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 19 at 3:18 PM
$KYNB Review article discusses the mechanisms of HIF-PH inhibitors like Roxadustat in anemia and inflammation. Good scientific background for the drug class. https://www.sciencedirect.com/science/article/pii/S2590006426003443
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 19 at 3:18 PM
$KYNB New study explores the potential of Roxadustat in lupus nephritis — a promising signal for treating multifactorial anemia in autoimmune kidney disease. https://www.researchgate.net/publication/407153617_Roxadustat_in_lupus_nephritis_a_novel_therapeutic_signal_for_multifactorial_anaemia
0 · Reply
mjtwins16
mjtwins16 Jun. 16 at 7:12 AM
$KYNB https://www.auntminnie.com/clinical-news/molecular-imaging/nuclear-medicine/article/15827697/new-immunopet-tracer-shows-promise-in-prostate-cancer
2 · Reply
MaxMiamiFl
MaxMiamiFl Jun. 15 at 3:33 PM
1 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 15 at 1:05 PM
$KYNB New meta-analysis published on PubMed shows that Roxadustat significantly improves hemoglobin levels and reduces transfusion dependence in patients with lower-risk MDS. Supportive data for Kyntra’s upcoming Phase 3 program. https://pubmed.ncbi.nlm.nih.gov/42270371/
0 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 13 at 11:31 AM
$KYNB Renaissance Technologies and ADAR1 Capital Management appear to have opened their KYNB positions this year, based on Q1 2026 13F filings. Renaissance is a legendary quantitative hedge fund that relies on data-driven models and systematic trading, while ADAR1 is a healthcare-focused manager that invests with deep sector research and biotech expertise. Their presence suggests KYNB has already passed both a quantitative screen and a specialized fundamental review. https://www.marketbeat.com/stocks/NASDAQ/KYNB/institutional-ownership/
1 · Reply
ARKADIY_PAROVOZOV
ARKADIY_PAROVOZOV Jun. 13 at 10:14 AM
$KYNB Я предполагаю, что вчерашнее движение было вызвано неоднозначными факторами: новостной импульс от доктора Zeidan. Вероятно, это https://stocktwits.com/ARKADIY_PAROVOZOV/message/656013294 в первую очередь привлекло мелких ритейлеров и торговых роботов, в то время как портфель заказов и объем продаж указывают на то, что некоторые крупные покупатели, возможно, воспользовались предложением. Однако это всего лишь мои предположения.
0 · Reply
Hanse2014
Hanse2014 Jun. 12 at 9:25 PM
$KYNB today 461k , very interesting, never saw it in the last year
1 · Reply
MaxMiamiFl
MaxMiamiFl Jun. 12 at 5:46 PM
$KYNB coukd mean nothing....could mean a lot: "I won't comment on any business development activities, which are ongoing at this point in time."
0 · Reply
MaxMiamiFl
MaxMiamiFl Jun. 12 at 5:10 PM
$KYNB https://seekingalpha.com/article/4902769-kyntra-bio-inc-kynb-q1-2026-earnings-call-transcript
2 · Reply
Waikiki2010
Waikiki2010 Jun. 12 at 4:39 PM
$KYNB Something is happening, volume is picking up, more than 200k already today.
4 · Reply
MaxMiamiFl
MaxMiamiFl Jun. 12 at 3:31 PM
$KYNB Did anyone listen to the meeting? and hints of anything? or same BS?
0 · Reply
MaxMiamiFl
MaxMiamiFl Jun. 12 at 1:43 PM
$KYNB MERGE!!! SELL!!!!....DO SOMETHING!!!!
0 · Reply
Itsybitsybeanbag
Itsybitsybeanbag Jun. 12 at 12:37 AM
$KYNB “Phase 3 MATTERHORN trial showed that more patients receiving roxadustat achieved transfusion independence vs. placebo (48% vs. 33%; p=0.22)” Too bad it ain’t statistically significance, actually a p. value of 0.22 would normally sway one away from even considering a Ph3… this is a crazy waste of money.
2 · Reply